Previous 10 | Next 10 |
HOLLISTON, Mass. , Aug. 13, 2020 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspan™ technology for the treatment of esopha...
Biostage ( OTC:BSTG ): Q1 GAAP EPS of -$0.24. Operating cash of $0.8M. Press Release More news on: Biostage, Inc., Earnings news and commentary, Healthcare stocks news, ,
HOLLISTON, Mass. , May 14, 2020 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspan™ technology, today announced its financi...
HOLLISTON, Mass. , March 27, 2020 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing next-generation esophageal implants, today announced its financial results for the three and twelve months ended December 31, 2019 ...
The FDA has approved Biostage's ( OTC:BSTG ) IND application for the Cellspan Esophageal Implant (CEI) to treat patients with end-stage esophageal disease that require a segmental surgical resection to repair the diseased tissue. More news on: Biostage, Inc., Healthcare stocks news,...
HOLLISTON, Mass. , March 20, 2020 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) (Biostage or the Company), a bioengineering company developing next-generation esophageal implants, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's I...
HOLLISTON, Mass. , Feb. 20, 2020 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, today announced that it has submitted its official response to the formal letter from the U.S. ...
HOLLISTON, Mass. , Jan. 2, 2020 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, received the anticipated formal response from the U.S. Food and Drug Administration (FDA) related to the C...
HOLLISTON, Mass. , Dec. 3, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, today announced that it was notified via email on November 27, 2019 by the U.S. Food and Drug Administra...
Phoenix, Arizona--(Newsfile Corp. - November 25, 2019) - The Stock Day Podcast welcomed Biostage, Inc. (OTCQB: BSTG) ("the Company"), a bioengineering company that is developing next-generation esophageal implants. CEO of the Company, Jim McGorry, joined Stock Day host Everett Jolly. Jolly b...
News, Short Squeeze, Breakout and More Instantly...
Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024. Received $0.5 million in convertible debt from Company’s CEO in February 2024. Hollisto...
Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following Colectomy Established a Collaboration with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproduct...
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate o...